MediciNova Stock Falls on Topline Results from Phase 2 Trial for Fatty Liver Disease Treatment

By Kelly CloonanShares of MediciNova declined after topline results from a Phase 2 trial for the company's potential treatment for hypertriglyceridemia and nonalcoholic fatty liver disease did not show statistical significance in reducing liver fat versus a placebo.The stock fell 13% to $2.25 in pr…